Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Looks like they'll be spreading Jam until 2021. That means more sales for NCYT for the winter season and if we are developing a lateral flow test of our own, we get more time to develop it without losing market space.
Massive losses too, I suppose that happens when you have very little to sell.
https://www.lse.co.uk/rns/AVCT/interim-results-for-the-period-ended-30-june-2020-fa3bwe8es9tx53k.html
AVCT Financial Highlights
· Fundraisings completed during the period raising £53.8 million to expand Diagnostics and Therapeutics programmes.
· Cash balance increased to £54.5 million (30 June 2019: £5.6 million; 31 December 2019: £8.8 million).
· Revenues increased to £1.8 million (6 months to 30 June 2019: £1.1 million; 17 months to 31 December 2019: £5.5 million).
· Operating loss of £8.1 million (6 months to 30 June 2019: £6.6 million; 17 months to 31 December 2019: £18.0 million), with research and amortisation of development costs increasing to £4.2 million (6 months to 30 June 2019: £2.9 million; 17 months to 31 December 2019: £10.1 million).
· Increased R&D investment leading to reported loss of £7.0 million (6 months to 30 June 2019: £5.7 million, 17 months to 31 December 2019: £15.6 million).
Short of votes, any PIs that have not voted email Mandy ASAP.
https://twitter.com/primerdesignltd/status/1309441194850684928?s=21
mandy.cowling@novacyt.com
I noticed on the link below, that Voleon doesn't have any short positions opened above 1.18%. Perhaps it means they limit their exposure on one share to 1.18%? If that's the case, they won't average down by opening more shorts at a higher share price and that might help us move more freely in the coming days.
http://legacy.whalewisdom.com/short_position/holder/voleon-capital-management-lp
Petelutton, you've made two negative posts since joining this board. We've been on an upward trend since mid June and the last few days have been bad across all markets. If you won't see value here, jog on.
Great to see PGMs will still be required by electric cars, another tick in the box for our product and one less thing the derampers can moan about.
Calamari,
We'll never know the reason for timing, perhaps a bidder has suggested he runs operations after they buy us out, he knows us well for because of previous DD carried out?
Or you might be looking for an explication or conspiracy theory when there isn’t one.
Antibody test RNS can drop any time, it won’t take much to move us now with sentiment returning. Anyone else think we have a decent antibody test order lined up soon as we launch? It feels like we were asked to make that lab based test...
And the shorts will need to close at some point.